Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
暂无分享,去创建一个
Steven P. Gygi | Joshua E. Elias | S. Gygi | D. Selkoe | J. Elias | Dennis J. Selkoe | Matthew L. Hemming | M. Hemming
[1] J. Tang,et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] B. Storrie,et al. Both Post‐Golgi and Intra‐Golgi Cycling Affect the Distribution of the Golgi Phosphoprotein GPP130 , 2007, Traffic.
[3] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. , 2001, Nature neuroscience.
[4] R. Iozzo,et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity , 2007, Oncogene.
[5] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[6] M. Ohno,et al. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.
[7] R. Klein,et al. Bidirectional Eph-ephrin signaling during axon guidance. , 2007, Trends in cell biology.
[8] S. Zaina,et al. The Soluble Type 2 Insulin-like Growth Factor (IGF-II) Receptor Reduces Organ Size by IGF-II-mediated and IGF-II-independent Mechanisms* , 1998, The Journal of Biological Chemistry.
[9] Stephen Abela,et al. Dementia in Malta: Experiences of dementia patients and their caregivers , 2009, Alzheimer's & Dementia.
[10] D. Price,et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice , 2008, Proceedings of the National Academy of Sciences.
[11] Shinobu Inagaki,et al. Requirement of the transmembrane semaphorin Sema4C for myogenic differentiation , 2005, FEBS letters.
[12] Alzheimer’s Association,et al. 2009 Alzheimer's disease facts and figures , 2009, Alzheimer's & Dementia.
[13] P. Jeffrey,et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. , 2007, Journal of neurochemistry.
[14] D. Selkoe,et al. Generation of amyloid β protein from its precursor is sequence specific , 1995, Neuron.
[15] R. Doms,et al. Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme , 2000, The Journal of Biological Chemistry.
[16] B. Hyman,et al. The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate* , 2005, Journal of Biological Chemistry.
[17] V. Lee,et al. BACE1 regulates voltage-gated sodium channels and neuronal activity , 2007, Nature Cell Biology.
[18] S. Kitazume,et al. Characterization of α2,6-Sialyltransferase Cleavage by Alzheimer's β-Secretase (BACE1)* , 2003, The Journal of Biological Chemistry.
[19] J G Flanagan,et al. Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.
[20] Xiuli Wu,et al. The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.
[21] D. Selkoe,et al. gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. , 2003, Biochemistry.
[22] M. Citron. β‐secretase as a target for the treatment of Alzheimer's disease , 2002 .
[23] T. Südhof,et al. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. , 2004, The Journal of biological chemistry.
[24] Roland L. Dunbrack,et al. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. , 2000, Journal of molecular biology.
[25] Philippe Soriano,et al. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. , 1999, Genes & development.
[26] M. Wolfe. Inhibition and modulation of γ-secretase for Alzheimer’s disease , 2008, Neurotherapeutics.
[27] Ray-Jade Chen,et al. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. , 2008, Journal of molecular endocrinology.
[28] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[29] M. Citron. Beta-secretase as a target for the treatment of Alzheimer's disease. , 2002, Journal of neuroscience research.
[30] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[31] N. Hooper,et al. The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. , 2004, European journal of biochemistry.
[32] P. Jeffrey,et al. Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .
[33] T. Furuyama,et al. Sema4C, a Transmembrane Semaphorin, Interacts with a Post-synaptic Density Protein, PSD-95* , 2001, The Journal of Biological Chemistry.
[34] R. Doms,et al. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. , 2000, The Journal of biological chemistry.
[35] R. Henriksson,et al. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? , 2007, European journal of cancer.
[36] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[37] E. Birney,et al. The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.
[38] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[39] S. Kitazume,et al. Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). , 2003, The Journal of biological chemistry.
[40] B. de Strooper,et al. Regulated Intramembrane Proteolysis of the Interleukin-1 Receptor II by α-, β-, and γ-Secretase* , 2007, Journal of Biological Chemistry.
[41] Charles Darwin,et al. Experiments , 1800, The Medical and physical journal.
[42] T. Südhof,et al. Cleavage of Amyloid-β Precursor Protein and Amyloid-β Precursor-like Protein by BACE 1* , 2004, Journal of Biological Chemistry.
[43] J. D. Wit,et al. Role of semaphorins in the adult nervous system , 2003, Progress in Neurobiology.
[44] D. Selkoe,et al. Selective ectodomain phosphorylation and regulated cleavage of beta‐amyloid precursor protein. , 1994, The EMBO journal.
[45] E. Hébert. Mannose-6-phosphate/Insulin-like Growth Factor II Receptor Expression and Tumor Development , 2006, Bioscience reports.
[46] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[47] D. Selkoe,et al. Ectodomain Phosphorylation of β-Amyloid Precursor Protein at Two Distinct Cellular Locations* , 1997, The Journal of Biological Chemistry.
[48] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[49] Joshua E. Elias,et al. Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements , 2008, PLoS biology.
[50] D. Selkoe,et al. Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor* , 2005, Journal of Biological Chemistry.
[51] D. Schlatter,et al. Substrate and Inhibitor Profile of BACE (β-Secretase) and Comparison with Other Mammalian Aspartic Proteases* , 2002, The Journal of Biological Chemistry.
[52] H. M. El-Shewy,et al. The Insulin-like Growth Factor Type 1 and Insulin-like Growth Factor Type 2/Mannose-6-phosphate Receptors Independently Regulate ERK1/2 Activity in HEK293 Cells* , 2007, Journal of Biological Chemistry.
[53] R. Vassar,et al. Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .
[54] Steven P Gygi,et al. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. , 2006, Journal of proteome research.
[55] S. Kar,et al. The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system , 2004, Brain Research Reviews.
[56] P. Wong,et al. BACE1 Knock-Outs Display Deficits in Activity-Dependent Potentiation of Synaptic Transmission at Mossy Fiber to CA3 Synapses in the Hippocampus , 2008, The Journal of Neuroscience.
[57] H. Lipp,et al. Mice with Combined Gene Knock-Outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members , 2000, The Journal of Neuroscience.
[58] D. Selkoe,et al. Generation of amyloid beta protein from its precursor is sequence specific. , 1995, Neuron.
[59] A. Linstedt,et al. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. , 2004, Molecular biology of the cell.
[60] B. de Strooper,et al. The Cell Adhesion Protein P-selectin Glycoprotein Ligand-1 Is a Substrate for the Aspartyl Protease BACE1* , 2003, Journal of Biological Chemistry.
[61] D. Selkoe,et al. Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease , 2007, PLoS medicine.
[62] D. Riddell,et al. Characterization of the Ectodomain Shedding of the β-Site Amyloid Precursor Protein-cleaving Enzyme 1 (BACE1)* , 2003, Journal of Biological Chemistry.
[63] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[64] Steven P Gygi,et al. The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. , 2008, Journal of proteome research.
[65] Jeffrey A. Golden,et al. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart , 1996, Nature.
[66] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.